secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anika Therapeutics, Inc. (ANIK)
CIK:        0000898437
Form:       8-K
Filed at:   2023-04-13T23:59:59+00:00
Accession:  0001193125-23-100714
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anika enters cooperation with Caligan, appoints director, authorizes $20M buyback
--------------------------------------------------------------------------------

- Appointed Gary Fischetti as Class III director; Board expands to eight members.
- Authorized $20M share repurchase: $5M accelerated, $5M open market, $10M subject to positive cash flow.
- Formed Capital Allocation Committee with Fischetti, Henneman, and Thompson.
- Caligan agreed to standstill and voting commitments supporting Board's 2023 slate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/898437/000119312523100714/0001193125-23-100714-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/898437/000119312523100714/d438476d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-100714

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer